Home/Pipeline/AstraZeneca Collaboration Program(s)

AstraZeneca Collaboration Program(s)

Not Disclosed

Discovery/Pre-clinicalActive

Key Facts

Indication

Not Disclosed

Phase

Discovery/Pre-clinical

Status

Active

Company

PepLib Biotech

About PepLib Biotech

PepLib Biotech is a China-based, privately held biotech focused on next-generation peptide drug discovery. The company has built a suite of proprietary technology platforms, including peptide library generation and screening technologies, to accelerate the identification of novel therapeutic candidates. It has secured high-profile partnerships with Novartis, Eli Lilly, and AstraZeneca, indicating validation of its platform, and has progressed to a Series B financing round to advance its pipeline. The company's strategy combines internal pipeline development with strategic out-licensing and collaboration deals.

View full company profile

Other Not Disclosed Drugs

Drug	Company	Phase	Status
SAGE-689	Sage Therapeutics	Phase 1	Paused
SAGE-904	Sage Therapeutics	Preclinical	Research
BO-212	Highlight Therapeutics	Research	Active
Newzen-138	Newzen Pharma	Not Disclosed	Active
Immunozen	Newzen Pharma	Not Disclosed	Active
Newzen-40	Newzen Pharma	Not Disclosed	Active
AbbVie Partnership Program(s)	EvolveImmune Therapeutics	Pre-clinical	Active
FYB209	Formycon	Preclinical/Technical Development	Active
FYB210	Formycon	Preclinical/Technical Development	Active
Undisclosed Target	Libra Therapeutics	Discovery	Active
Eli Lilly Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
SRSD101	Sirius Therapeutics	Phase 1	Active